Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 100.00% is 103% above its 5-year average of -3662.36%, near the high end of its 5-year range (-12618.40%–100.00%).
As of the fiscal period ended Tuesday, June 30, 2026. 103.93% above its 12-month average of -2543.49%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
100.00%
GROSS MARGIN AVG TTM
-2543.49%
GROSS MARGIN AVG 3Y
-2468.25%
GROSS MARGIN AVG 5Y
-3662.36%
GROSS MARGIN AVG 10Y
-1629.76%
GROSS MARGIN AVG 15Y
-1190.17%
GROSS MARGIN AVG 20Y
-681.38%
CURRENT VS TTM AVG
+103.93%
CURRENT VS 3Y AVG
+104.05%
CURRENT VS 5Y AVG
+102.73%
CURRENT VS 10Y AVG
+106.14%
CURRENT VS 15Y AVG
+108.40%
CURRENT VS 20Y AVG
+114.68%
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+141.66%
vs the sector median at left
Celldex Therapeutics, Inc.
Market Cap
$2.07B
Gross Margin
100.00%
TTM Avg
-2543.49%
3Y Avg
-2468.25%
5Y Avg
-3662.36%
Market Cap
$2.07B
Gross Margin
99.55%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
-349.27%
Market Cap
$2.07B
Gross Margin
74.56%
TTM Avg
73.48%
3Y Avg
70.60%
5Y Avg
69.69%
Market Cap
$2.09B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.04B
Gross Margin
90.85%
TTM Avg
89.42%
3Y Avg
88.91%
5Y Avg
89.39%
Market Cap
$2.04B
Gross Margin
97.82%
TTM Avg
97.53%
3Y Avg
97.80%
5Y Avg
96.20%
Market Cap
$2.11B
Gross Margin
32.36%
TTM Avg
32.47%
3Y Avg
32.14%
5Y Avg
31.56%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | $2.07B | 100.00% | -2543.49% | -2468.25% | -3662.36% |
| Alvotech (ALVO)vs › | $2.07B | 60.45% | 60.99% | 17.21% | 44.81% |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.07B | 99.55% | 100.00% | 100.00% | -349.27% |
| Vericel Corporation (VCEL)vs › | $2.07B | 74.56% | 73.48% | 70.60% | 69.69% |
| Vera Therapeutics, Inc. (VERA)vs › | $2.09B | 0.00% | 0.00% | 0.00% | 0.00% |
| UroGen Pharma Ltd. (URGN)vs › | $2.04B | 90.85% | 89.42% | 88.91% | 89.39% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.04B | 97.82% | 97.53% | 97.80% | 96.20% |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 32.36% | 32.47% | 32.14% | 31.56% |
| Progyny, Inc. (PGNY)vs › | $2.03B | 24.57% | 22.67% | 22.13% | 21.88% |
| Fortrea Holdings Inc. (FTRE)vs › | $2.02B | 17.11% | 17.72% | 20.44% | 20.08% |
Gross Margin
100.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | -5593.33% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | -7324.11% |
| 2025-03-31 | -7470.36% |
| 2024-12-31 | 30.30% |
| 2024-09-30 | -1318.46% |
| 2024-06-30 | 68.09% |
| 2024-03-31 | -396.79% |
| 2023-12-31 | -636.53% |
| 2023-09-30 | 49.44% |
| 2023-06-30 | -9695.52% |
| 2023-03-31 | -2671.25% |
| 2022-12-31 | -1319.65% |
| 2022-09-30 | -5200.25% |
| 2022-06-30 | -12618.40% |
| 2022-03-31 | -9702.30% |
| 2021-12-31 | -4294.61% |
| 2021-09-30 | -8760.78% |
| 2021-06-30 | -255.06% |
| 2021-03-31 | -1756.93% |
| 2020-12-31 | -175.43% |
| 2020-09-30 | -1502.99% |
| 2020-06-30 | -4012.29% |
| 2020-03-31 | -328.70% |
| 2019-12-31 | -1065.61% |
| 2019-09-30 | -1933.15% |
| 2019-06-30 | -1309.93% |
| 2019-03-31 | -682.53% |
| 2018-12-31 | -478.63% |
| 2018-09-30 | -1166.52% |
| 2018-06-30 | -676.26% |
| 2018-03-31 | -437.73% |
| 2017-12-31 | -578.94% |
| 2017-09-30 | -458.49% |
| 2017-06-30 | -552.89% |
| 2017-03-31 | -1581.42% |
| 2016-12-31 | 99.95% |
| 2016-09-30 | -2101.22% |
| 2016-06-30 | -3468.68% |
| 2016-03-31 | -3837.45% |
| 2015-12-31 | 4136.87% |
| 2015-09-30 | 7069.20% |
| 2015-06-30 | 3298.81% |
| 2015-03-31 | 14716.26% |
| 2014-12-31 | -1729.79% |
| 2014-09-30 | -2278.29% |
| 2014-06-30 | -3970.95% |
| 2014-03-31 | -5806.25% |
| 2013-12-31 | -2771.61% |
| 2013-09-30 | 1877.96% |
| 2013-06-30 | 23554.64% |
| 2013-03-31 | 3.31% |
| 2012-12-31 | 2.63% |
| 2012-09-30 | 3.44% |
| 2012-06-30 | 6.77% |
| 2012-03-31 | 3.66% |
| 2011-12-31 | 3.12% |
| 2011-09-30 | 1.90% |
| 2011-06-30 | 0.56% |
| 2011-03-31 | 0.56% |
| 2010-12-31 | 81.97% |
| 2010-09-30 | 49.42% |
| 2010-06-30 | 41.31% |
| 2010-03-31 | 37.33% |
| 2009-12-31 | -77.41% |
| 2009-09-30 | 100.00% |
| 2009-06-30 | 100.00% |
| 2009-03-31 | 100.00% |
| 2008-12-31 | 100.00% |
| 2008-09-30 | 100.00% |
| 2008-06-30 | 100.00% |
| 2008-03-31 | 100.00% |
| 2007-12-31 | 388.33% |
| 2007-09-30 | 442.99% |
| 2007-06-30 | 100.00% |
| 2007-03-31 | -319.45% |
| 2006-12-31 | 100.00% |
| 2006-09-30 | 100.00% |
| 2006-06-30 | 100.00% |
| 2006-03-31 | -17.33% |
| 2005-12-31 | 100.00% |
| 2005-09-30 | 100.00% |
| 2005-06-30 | 100.00% |
| 2005-03-31 | 100.00% |
| 2004-12-31 | 100.00% |
| 2004-09-30 | 100.00% |
| 2004-06-30 | 100.00% |
| 2004-03-31 | 100.00% |
| 2003-12-31 | 100.00% |
| 2003-09-30 | 100.00% |
| 2003-06-30 | 100.00% |
| 2003-03-31 | 100.00% |
| 2002-12-31 | 99.99% |
| 2002-09-30 | 99.77% |
